SpeedWeed

MAY 18, 2021

Drug Enforcement Administration (DEA) quietly made an announcement that’s expected to have a profound and long-lasting impact on cannabis research and development in the United States. cannabis researchers. For years, NIDA and the DEA have promised to open up the sourcing of federally-approved research cannabis.

DEA 52

DEA Research and Development Data Cannabis 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA 51

DEA Clinical Trials THC Research and Development 51

Veriheal

JUNE 29, 2021

Did we ever stop to think that if we could legally utilize the plants in the first place that perhaps we wouldn’t develop terminal illnesses at such a high rate? A Push by Patients. Along with patients, a Seattle-based palliative care physician by the name of Dr. Sunil Aggarwal was also named in the lawsuit.

Therapy 64

Therapy DEA Patients Clinical Trials 64

SpeedWeed

SEPTEMBER 4, 2021

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. “DEA

DEA 52

DEA Research and Development Clinical Trials Extraction 52

Cannabis Law Report

JUNE 12, 2021

MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. The partnership will initiate the development of CBD and THC oral thin films for CURE’s clinical studies targeted at advancing veteran health.

DEA 45

DEA Pharmaceutical Research and Development Compliance 45

CannaMD

AUGUST 8, 2020

Researchers believe cannabis contains over 100 unique chemical compounds! Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential.

CBD 105

CBD DEA Research and Development Hemp 105

Canna Law Blog

MARCH 4, 2020

With respect to ketamine infusion therapy (which is the prime time attraction of ketamine clinics), the medical research based promise is for treatment of chronic neuropathic pain, chronic pain (instead of opioids), and various medication-resistant mental health disorders, including depression, bi-polar disorder, and PTSD (among others).

Therapy 106

Therapy Legalization Chronic Pain DEA 106

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 119

Research and Development Education Agriculture Patients 119

Veriheal

DECEMBER 28, 2021

Over the last few decades, the cannabis plant and its many components have been the focal point of research and stiff debate. D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

SpeedWeed

JULY 23, 2021

Denver is expanding Alzheimer’s research through the efforts of local company MedPharm. . The company plans to move forward with research efforts through a special Schedule I Researcher Licenses given specifically to the company by the Drug Enforcement Administration. Denver Company Moves Forward with Research License .

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

Cannabis Law Report

JANUARY 10, 2022

Panacea”), a leading United States biotechnology company focused on developing new therapeutic, cultivation, extraction and isolation techniques for high value natural products such as psychedelic-containing lifeforms and cannabis. is a Canadian biotechnology company providing cannabis testing and research services.

Research and Development 52

Research and Development Supply Chain DEA Events 52

Cannabis Law Report

DECEMBER 15, 2021

Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybin-containing mushrooms for authorized research purposes. market for research purposes is absolutely key for us as we look to expand our business in 2022,” he adds. “With their track-record of working with the U.S.

Supply Chain 52

Supply Chain Research and Development DEA Pharmaceutical 52

Cannabis Law Report

JULY 1, 2021

On June 30th, the Petrie-Flom Center announced the launch of a three-year research initiative , the Project on Psychedelics Law and Regulation (POPLAR) , which is supported by a generous grant from the Saisei Foundation. POPLAR will publish original law and policy research. What barriers exist to conducting psychedelics research?

Law 81

Law Research and Development Therapy DEA 81

SpeedWeed

MARCH 21, 2021

Trulieve offers Delta-8 in its TruPod vaporizer cartridges and TruClear Syringes, says Beau Williamson, Trulieve director of research and development. Typically, patients may experience some of the same analgesic and antiemetic effects as Delta-9,” he adds. RELATED: Dr. Ethan Russo Endorses 1% THC Limit for Hemp. RELATED: U.S.

Research and Development 40

Research and Development Hydroponic DEA Cannabinoids 40

Cannabis Law Report

JULY 9, 2021

Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. Joyce Cutler, Texas the Latest State to Legalize Psychedelic Medical Research, BLOOMBERG LAW (June 23, 2021), available at [link].

Law 81

Law Therapy Clinical Trials Research and Development 81

MedicalJane

JUNE 29, 2018

On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). Background.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Veriheal

DECEMBER 1, 2020

When it comes to scientific research and the way of Delta-8-THC, it is scarce. An outdated study from the early 1990s conducted on chemotherapy patients that were children showed just like Delta-9 that Delta-8 helped prevent vomiting. The DEA is Already Interfering. Way to go, DEA, on jumping the gun showing your true colors.

THC 52

THC DEA Research and Development Cannabinoids 52

Cannabis Law Report

JULY 12, 2019

By: James Holley, Molecular Biologist, Scientific Officer, Mike Robinson, Co-founder, Research Institute, and Dr. David Ostrow, M.D., Research Director. International Cannabinoid Cancer Research Institute (Draft 5). One patient died but it was ruled to be part of the course of their disorder and not a drug effect.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

United Patients Group

APRIL 3, 2023

A recommendation from a physician is simply permission (‘recommendation’) for the patient to use cannabis, which can be obtained in any state where medical marijuana is legal. Epidiolex, an FDA-approved medication containing CBD (cannabidiol), has been listed as Schedule 5 by the DEA since June 25th, 2019.

DEA 52

DEA Patients Conditions Cannabis 52

Cannabis Law Report

APRIL 21, 2022

MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . The full statement.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

SpeedWeed

AUGUST 11, 2021

According to Dr. Sue Sisley, President of the Scottsdale Research Institute and longtime cannabis researcher, this new study is sorely needed in the community. Veterans are demanding objective cannabis drug development research, and the state of Michigan is fulfilling our collective obligation to our beloved Veteran community.”.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

AUGUST 18, 2022

The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. Rick Doblin founded MAPS as an official 501(c)(3) non-profit research organization on April 8, 1986. Later that year, Doblin sued the DEA for the first time.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

The Cannigma

MAY 1, 2023

Named because it is the result of the joining two different chemical types – a ketone and an amine, ketamine was developed in 1962 as an alternative dissociative anesthetic drug to the potently hallucinogenic phencyclidine, known more commonly as PCP. It was becoming clear that another class of anesthetics was needed.

Blood Pressure 80

Blood Pressure Chronic Pain Research and Development Clinical Trials 80

Cannabis Law Report

JUNE 4, 2021

Dr. Titus has been involved in the development and investment of several industry-leading cannabis and industrial hemp businesses during his most recent career. Dr. Titus developed several prominent cannabis companies, including HempMeds, KannaLife Sciences Inc, and Kannaway, LLC.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

SpeedWeed

MARCH 21, 2021

Trulieve offers Delta-8 in its TruPod vaporizer cartridges and TruClear Syringes, says Beau Williamson, Trulieve director of research and development. Typically, patients may experience some of the same analgesic and antiemetic effects as Delta-9,” he adds. RELATED: Dr. Ethan Russo Endorses 1% THC Limit for Hemp. RELATED: U.S.

THC 52

THC Business DEA Cannabinoids 52

SpeedWeed

MARCH 17, 2021

Trulieve offers Delta-8 in its TruPod vaporizer cartridges and TruClear Syringes, says Beau Williamson, Trulieve director of research and development. Typically, patients may experience some of the same analgesic and antiemetic effects as Delta-9,” he adds. RELATED: Dr. Ethan Russo Endorses 1% THC Limit for Hemp. RELATED: U.S.

DEA 52

DEA Cannabinoids Research and Development THC 52

Kind Meds (Cannabis Education Blog)

SEPTEMBER 4, 2019

This cautionary tale is premised on the same goal that some dispensary owners, manufacturers, and stockholders are hypervigilant on, to the detriment of hemp patients. While the FDA continues to choke the progression of research and scientific developments regarding marijuana, it simultaneously cracks down on the big players of our industry.

Dispensary 69

Dispensary Research and Development Pets Patients 69

Sensi Seeds

NOVEMBER 28, 2018

But in an email correspondence conducted as research for this article, EFSA denies issuing any statement in relation to CBD in Spain. Food and Drug Administration (FDA) earlier this year, and convince the DEA to reclassify CBD from a Schedule I (most restrictive category) to a Schedule V drug (least restrictive category.)

CBD 71

CBD Seed-To-Sale Food Research and Development 71

Cannabis Law Report

APRIL 1, 2019

It aims to turn the plants’ chemical compounds into 2,500 5-milliliter bottles – the size of a teaspoon – of cannabis oil and sublingual drops for clinical trials among volunteer patients as early as July. It remains to be seen whether the Drug Enforcement Authority, or DEA, will designate cannabis zones for these farmers.

Research and Development 40

Research and Development Pharmaceutical Clinical Trials DEA 40

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Watch Video: The Press Release. NEWS PROVIDED BY. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Weedistry

MARCH 7, 2019

Marijuana Fights Cancer and Helps Manage Side Effects, Researchers Find. She had been screening brain cancer cells because they grow faster than normal cell lines and thus are useful for research purposes. The ID -1 gene is active during human embryonic development, after which it turns off and stays off.

THC 40

THC CBD Clinical Trials Research and Development 40

SpeedWeed

MARCH 5, 2021

Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Further, substances in these scheduling categories are only available to patients under the prescription of a physician – therefore making such a classification inapplicable to cannabis in those states that regulate its adult use.

Business 52

Business Policy Clinical Trials Research and Development 52

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and Cannabinoids: Health, Research and Regulatory Considerations (Position Paper). Marijuana and related substance misuse are complex issues impacting family medicine, patient health, and public health. Family physicians have a vested interest in policies that advance and protect the health of their patients and the public.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

The Cannigma

JULY 3, 2023

The clues we have from existing literature indicate that while it’s probably safe, there’s insufficient clinical research to confirm or dispel it. Happily, the body of research into cannabis and psychedelics (including MDMA) is expanding fast, and it’s likely that better data on their interactions will become available in the near future.

Research and Development 46

Research and Development Environment THC Microdosing 46

Kind Meds (Cannabis Education Blog)

SEPTEMBER 4, 2019

This cautionary tale is premised on the same goal that some dispensary owners, manufacturers, and stockholders are hypervigilant on, to the detriment of hemp patients. While the FDA continues to choke the progression of research and scientific developments regarding marijuana, it simultaneously cracks down on the big players of our industry.

Marijuana 40

Marijuana Research and Development Dispensary Pets 40